-
-
-
-
-
-
-
Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease
-
-
-
-
-
-
-
Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®
-
-
-
-
-
-
-
Amneal Reports Fourth Quarter and Full Year 2025 Financial Results
-
-
-
-
-
-
-
Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease
-
-
-
-
-
-
-
Amneal Pharmaceuticals (AMRX) Tops Q3 EPS by 3c, provides guidance
-
-
-
-
-
-
-
Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab)
-
-
-
-
-
-
-
Amneal Pharmaceuticals (AMRX) Tops Q2 EPS by 8c, raises guidance
-
1,204,710 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

